Does fibrinolytic therapy prevent hemodynamic decompensation in patients with intermediate-risk pulmonary embolism?
patients with intermediate-risk pulmonary embolism
fibrinolytic therapy
hemodynamic decompensationhard clinical
Fibrinolytic therapy prevents hemodynamic decompensation in intermediate-risk pulmonary embolism but significantly increases the risk of major hemorrhage and stroke.
In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Guy Meyer
Éric Vicaut
Thierry Danays
New England Journal of Medicine
Harvard University
Brigham and Women's Hospital
Université Paris Cité
Building similarity graph...
Analyzing shared references across papers
Loading...
Meyer et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d979dc5e5bcb4e3b836c71 — DOI: https://doi.org/10.1056/nejmoa1302097